BioCentury
ARTICLE | Clinical News

Regeneron combo fails to top Eylea alone in AMD study

September 30, 2016 7:00 AM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) said intravitreal injections of REGN2176-3 missed the primary endpoint in the ongoing Phase II CAPELLA study to treat wet age-related macular degeneration. The therapy, which combines the company's ophthalmic drug Eylea aflibercept with rinucumab, an antibody against platelet derived growth factor receptor B ( PDGFRB; PDGFR1; CD140B), failed to significantly improve visual acuity compared with Eylea alone.

After 12 weeks, both of the study's doses of REGN2176-3 led to a 5.8-letter improvement from baseline in best corrected visual acuity (BVCA), compared with 7.5 letters for Eylea alone. Ocular adverse events were more common in the REGN2176-3 groups, which Regeneron said was driven by an increase in conjunctival hemorrhage, eye irritation and eye pain. ...